Procognia Limited Today Announced That It Has Completed the Feasibility Stage of Its Cooperation Agreement with Teva Pharmaceutical Industries Limited (TEVA) for the Development of a Biopharmaceutical Product
9/4/2007 10:47:31 AM
ASHDOD, Israel--(BUSINESS WIRE)--Procognia Israel (TASE:PRCG) today announced that it has completed the technology feasibility stage outlined in its September 2006 agreement with Teva for the development of a biopharmaceutical product. Under this agreement, Procognia Israel supplies analytical services and the right of exclusive use of specialized technology that it has developed to identify and analyze sugar residues on proteins. This agreement is outlined in section 184.108.40.206.1 of the company's prospectus dated February 26, 2007 ["agreement"].